TDM4529G; An Open-Label Multicenter Extension Study of Trastuzumab-MCC-DM1 (T-DM1) Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Treated With the Equivalent T-DM1 Regimen in a Genentech and/or F. Hoffmann-La Roche Ltd.-Sponsored T-DM1 Study
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
This is a global, multicexpressionDISABLEDs) at the time of the parent study closure are eligible for continued treatment on this protocol.
Description
This is a global, multicexpressionDISABLEDs) at the time of the parent study closure are eligible for continued treatment on this protocol.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
20 Apr 2024.
Study ID: 1105005391 (1011-14)
